Trial Profile

NiTraSarc Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas - The NiTraSarc Phase II Trial

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; Trabectedin (Primary)
Indications Leiomyosarcoma; Liposarcoma; Soft tissue sarcoma; Synovial sarcoma
Focus Adverse reactions; Therapeutic Use
Acronyms NiTraSarc

Most Recent Events

06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
26 May 2023 According to PharmaMar media release, results from this study will be presented at the annual meeting of the American Society of Clinical26 May 2023 Oncology (ASCO), to be held on June 2-6, 2023, both virtually and in situ in Chicago, USA.
07 Nov 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com